Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 17/20 | 1.00 |
| ▸ | CRBN | Q96SW2 | 17/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.68 |
| ▸ | TNF | P01375 | 1/20 | 0.68 |
| ▸ | IL1B | P01584 | 1/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.68 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15930069 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL29601554 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL2110965 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL1398974 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL15930063 | 1.00 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19611941 | 0.93 | DDB1 (0.87) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18263911 | 0.93 | DDB1 (0.87) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18263926 | 0.93 | DDB1 (0.87) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19359185 | 0.90 | DDB1 (0.82) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL29923364 | 0.90 | DDB1 (0.82) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266514-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180044318-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORP (US) | 2018-02-15 | — | — | US | disclosed |
| US-9822093-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2017-11-21 | — | — | US | disclosed |
| WO-2017134476-A1 | METHOD FOR THE PRODUCTION OF POMALIDOMIDE | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2017-08-10 | — | — | WO | disclosed |
| US-20160297791-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORP (US) | 2016-10-13 | — | — | US | disclosed |
| US-9394274-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2859895-A1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels | CELGENE CORPORATION (US) | 2015-04-15 | — | — | EP | disclosed |
| EP-2305663-B1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels | CELGENE CORP (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140256950-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-09-11 | — | — | US | disclosed |
| US-8785644-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2014-07-22 | — | — | US | disclosed |
| US-6555554-B2 | 2,6-dioxopiperidin; antiinflammatory agent; reduces tumor necrosis factor alpha levels and/or increases cAMP | CELGENE CORPORATION | 2003-04-29 | — | — | US | disclosed |
| EP-1285916-A1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels | CELGENE CORPORATION (US) | 2003-02-26 | — | — | EP | disclosed |
| US-20020183360-A1 | Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels | MULLER GEORGE W (US) | 2002-12-05 | — | — | US | disclosed |
| US-6476052-B1 | Isoindolines, method of use, and pharmaceutical compositions | CELGENE CORPORATION | 2002-11-05 | — | — | US | disclosed |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | MULLER GEORGE W (US) | 2002-04-18 | — | — | US | disclosed |
| US-6335349-B1 | AGENTS THAT REDUCE LEVELS OF TUMOR NECROSIS FACTOR; ANTICARCINOGENIC AND ANTIINFLAMMATORY AGENTS; TREATMENT OF AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2002-01-01 | — | — | US | disclosed |
| US-6316471-B1 | TREATING INFLAMMATORY OR AUTOIMMUNE DISEASES | CELGENE CORPORATION | 2001-11-13 | — | — | US | disclosed |
| US-6281230-B1 | TREATING INFLAMMATION, INFLAMMATORY DISEASE OR AUTOIMMUNE DISEASE IN A MAMMAL | CELGENE CORPORATION | 2001-08-28 | — | — | US | disclosed |
| EP-0925294-A1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998003502-A1 | SUBSTITUTED 2(2,6-DIOXOPIPERIDIN-3-YL)PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORPORATION (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297791-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | TNF, TRAF2, IL1A | DDB1 1407/4885CRBN 3082/4885IKZF3 835/4885 |
| US-20020183360-A1 | Substituted 2-(2,6-dioxopiperidin-3-YL)-phthalimides and -1-oxoisoindolines and method of reducing TNFalpha levels | TNF, TNFRSF1A, TRAF2 | DDB1 1125/4885CRBN 3437/4885IKZF3 790/4885 |
| US-10266514-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | TNF, TRAF2, IL1A | DDB1 1407/4885CRBN 3082/4885IKZF3 835/4885 |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | TNF, OPRK1, OPRD1 | DDB1 3697/4885CRBN 4469/4885IKZF3 1543/4885 |
| US-20140256950-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | TNF, TRAF2, IL1A | DDB1 1407/4885CRBN 3082/4885IKZF3 835/4885 |
| US-20180044318-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | TNF, TRAF2, IL1A | DDB1 1407/4885CRBN 3082/4885IKZF3 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.